William Stern, PhD; Nozer Mehta, PhD; and Stephen Carl, PhD; review a highly developed, clinically proven platform technology that enables the oral delivery of peptides, overcoming the hurdles inherent to oral peptide delivery.
Jyothi Thundimadathil, PhD, indicates that even though shorter in vivo half-life of peptides is a concern, recent advances in drug delivery systems and peptide modification are expected to override those difficulties.
PLATFORM TECHNOLOGY – Tumor-Targeting Platform Delivers the Next Generation of Pediatric Cancer Drugs
Contributor Cindy H. Dubin examines the desperate need for therapies that can address underserved populations, eradicate the cancer state without severe complications, and prolong the lifespan of the patient after diagnosis, and how NanoSmart Pharmaceuticals, with its unique tumor-targeting platform, has taken on that challenge.
DRUG DELIVERY – HEPtune: A Process of Conjugating a Naturally Occurring Sugar Molecule, Heparosan, to a Drug for Enhanced Drug Delivery
Paul L. DeAngelis, PhD, shows how heparosan is a stealthy molecule well suited for use as a drug delivery vehicle due to its natural origin and properties in the body. Therefore, heparosan-modified therapeutics may offer improved pharmacokinetics, drug performance properties, as well as new options for treatment and hope for patients.
DRUG DEVELOPMENT – Analysis & Materials Characterization – Surface Characterization of Pharmaceuticals by X-Ray Photoelectron Spectroscopy
Jeffrey Shallenberger, MS; and Robert W. Lee, PhD; use X-ray photoelectron spectroscopy (a quantitative, surface-sensitive spectroscopy capable of probing the local chemical bonding of inorganic and organic materials) to quantify the amount of an API and two excipients.
EXECUTIVE INTERVIEW – Ariel Pharmaceuticals, Inc: Reducing Shareholder Risk Through Expedited Clinical Development
Executive Summary: Steve Orndorff, President and CEO of Ariel, discusses his company’s drugs in development and plans for the future.
Robert Becker, PhD, Chief Research Officer at Aptalis Pharma, discusses Patient Centric Drug Delivery and the company’s role in supporting patient compliance and driving commercial value through new drug formulations.
Dieter Scherer, PhD; Eva Alvarez-Gonzalez, PhD; and Anthony Pettigrew, MSc; examine a proprietary non-protic, aqueous-free ocular delivery system with the potential to provide an alternative approach in particular for poorly soluble drugs.
Frost & Sullivan Analysts Jennifer Brice and Deborah Toscano observe how the arrival of biosimilars, or highly similar copies of biopharmaceutical products, to the US market is imminent, and although they have been available elsewhere for several years, physicians and other key stakeholders in the US have only recently begun to anticipate their arrival.
FORMULATION DEVELOPMENT – KinetiSol: A New Processing Paradigm for Amorphous Solid Dispersion Systems
Dave A. Miller, PhD; James C. DiNunzio, PhD; Justin R. Hughey, PhD; Robert O. Williams III, PhD; and James W. McGinity, PhD; review how a novel fusion-based process for the production of amorphous solid dispersion systems has recently been adapted to pharmaceutical processing and is providing novel solutions for difficult-to-process compounds.
EXCLUSIVE ONLINE CONTENT
Biogen Inc. and Denali Therapeutics Inc. recently announced they have signed a binding agreement to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for….
RedHill Biopharma Ltd. recently announced approval from the Mexican Federal Committee for the Protection against Sanitary Risks (COFEPRIS) for the company’s Clinical Trial Authorization (CTA) application for….
Immatics N.V. recently announced the extension of its cell therapy manufacturing collaboration with The University of Texas Health Science Center at Houston (UTHealth)….
Catalent recently announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion, which will add over….
Editas Medicine Enters Into Strategic Partnership With Catalent to Support Gene-Editing Medicine Pipeline
Editas Medicine, Inc. and Catalent recently announced they have entered into a strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical supply of….